Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | APLNR | P35414 | 2/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.49 |
| ▸ | GNRHR | P30968 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teprotide SCHEMBL11855843 | 1.00 | F13A1 (0.52) | F13A1TGM2CXCR4APLNRABCC2 | |
| Teprotide SCHEMBL8158703 | 0.97 | CXCR4 (0.51) | F13A1TGM2CXCR4APLNRABCC2 | |
| SCHEMBL11872216 | 0.96 | GNRHR (0.50) | F13A1TGM2CXCR4APLNRABCC2 | |
| SCHEMBL11867492 | 0.94 | GNRHR (0.51) | F13A1TGM2CXCR4APLNRABCC2 | |
| Teprotide SCHEMBL613757 | 0.92 | GNRHR (0.57) | F13A1TGM2APLNRABCC2GNRHR | |
| SCHEMBL11863118 | 0.89 | IL23R (0.51) | F13A1TGM2CXCR4CTSLCTSS | |
| SCHEMBL11863142 | 0.89 | IL23R (0.51) | F13A1TGM2CXCR4CTSLCTSS | |
| SCHEMBL24120770 | 0.87 | CXCR4 (0.55) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL11865471 | 0.86 | CXCR4 (0.46) | F13A1TGM2CXCR4APLNRABCC2 | |
| SCHEMBL11872436 | 0.86 | CASP1 (0.51) | CXCR4CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1618 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3544597-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | Alkalidx, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| WO-2018098273-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | ALKALIDX, INC. (US) | 2018-05-31 | — | — | WO | claimed |
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20180118699-A1 | SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2018-05-03 | — | — | US | claimed |
| US-20170299598-A1 | Methods and Monitoring of Treatment With A DLL4 Antagonist | ONCOMED PHARMACEUTICALS, INC. | 2017-10-19 | — | — | US | claimed |
| US-20170166632-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1991012001-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| EP-0419048-A2 | Substituted pyrimidinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-03-27 | — | — | EP | claimed |
| EP-0412594-A2 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-13 | — | — | EP | claimed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | claimed |
| EP-0409332-A2 | Substituted triazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | claimed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | claimed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0401030-A2 | Angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118699-A1 | SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE | KCNH2, KCNK5, KCNN3 | F13A1 3653/4885TGM2 4510/4885CXCR4 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.